肝素对毒素诱导的消费凝血病的影响:随机对照试验的元分析
Yu-Ning Huang1, Wei-Chuan Chang2, Yun-Kuan Lin3
1Department of Anesthesiology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, No. 707, Sec. 3, Zhongyang Rd., Hualien City, Hualien County 970473, Taiwan.
概括
氨酸并没有显著降低毒液诱导消费凝血病 (VICC) 的死亡率,这是一种严重的蛇并发症. 目前的证据不足,表明需要进一步的试验来确认肝素.
科学领域:
- 毒理学 毒理学 毒理学
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 毒素诱导的消耗凝血病 (VICC) 是蛇咬的关键并发症,经常导致严重出血.
- 对于除了抗毒药之外的治疗方法,如肝素,用于管理VICC,证据有限.
研究的目的:
- 系统地审查,元分析和执行试验序列分析 (TSA) 关于肝素在治疗VICC中的疗效.
主要方法:
- 2024年8月11日,在八个数据库中对对VICC的肝素进行了随机对照试验 (RCT) 的系统搜索.
- 在元分析和TSA中包括了六个RCT.
主要成果:
- 肝素没有显著降低VICC患者的死亡率 (风险比:0.65;95%CI:0.391.10).
- 在肝素和对照组之间没有观察到临床结果的显著差异.
- TSA指出,对肝素对VICC死亡率的影响的证据不足,这表明在未来的RCT中需要大约741名患者.
结论:
- 目前的研究结果表明,肝素可能不会显著影响VICC结果.
- 有限的样本大小需要进一步的研究,以提供关于肝素在管理VICC中的作用的确证据.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
Extrinsic and Intrinsic Pathways of Hemostasis
5.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.3K
Anticholinesterase Agents: Poisoning and Treatment
783
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
783
Introduction to Hemostasis
5.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.4K


